Special Issue "Biologically Active Small Molecules Inspired by Plant Secondary Metabolites"
Deadline for manuscript submissions: 31 October 2019
It would seem that more than 500 centuries ago, our closest human relatives―the Neanderthals―used to place Ephedra plant flowers into graves. This might be the most ancient example of paleoethnobotany. As questionable as this statement might be, undoubtedly, the Plant Kingdom has been the most prodigal source of medicines for over 20 centuries.
The last four decades have witnessed a resurgence of interest in plant product research. Numerous and varied are the reasons for this:
- Ever-increasing difficulty in developing new drugs;
- The success of the natural product approach;
- The uniqueness of plant secondary metabolites;
- The impact of new screening methods and analytic techniques.
Unfortunately, plant secondary metabolites are not necessarily the best compounds for pharmaceutical uses, for the following reasons:
- Limitations may exist that prevent the acquisition of sufficient biomass;
- Isolation procedures may be long and expensive;
- The structure of the secondary metabolites may be too complex to allow total synthesis;
- The pharmacological profile may be promiscuous;
- Toxicological aspects may cause concern;
- Oral bioavailability can be too low.
For all of the above reasons, medicinal chemists use to prepare analogues of the starting secondary metabolites in order to unveil sound structure–activity relationships (SAR) and possibly overcome the above limitations.
This Special Issue is designed to scrutinize recent developments in the medicinal chemistry of biologically relevant compounds that were inspired by plant-derived compounds.
Between 1980 and 2013, 20% of the new drugs introduced into the market were either natural products or natural products derivatives, with the latter being highly predominant (18%). The contribution of natural product derivatives to the physician panoply is expected to rise in the next decade. The colleagues that would like to share their valuable work in the field by contributing to this Special Issue of Molecules will give shine to the issue, of course, and would possibly confer higher chances to this prophecy.
Assoc. Prof. Giovanni Lentini
Dr. Maria Maddalena Cavalluzzi
Prof. Solomon Habtemariam
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Drug discovery
- Secondary metabolites
- Natural product scaffolds
- Structure–activity relationships